Novartis AG

Compare

23 Followers

NOT Stock Chart & Stats

€107.20

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€107.20

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€79.74 - €114.60

Previous CloseN/A

Volume24.84K

Average Volume (3M)909.00

Market Cap

CHF214.11B

Enterprise Value€208.96B

Total Cash (Recent Filing)CHF7.00B

Total Debt (Recent Filing)CHF32.64B

Price to Earnings (P/E)17.8

Beta0.24

Next Earnings

Feb 04, 2026

EPS Estimate

1.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.95

Shares Outstanding2,112,421,900

10 Day Avg. Volume1,167

30 Day Avg. Volume909

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF110.52

Price Target Upside3.10% Upside

Rating ConsensusHold

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Pipeline And Sales GrowthKey product launches such as remibrutinib, ianalumab, and Pluvicto may significantly drive sales growth, boosting confidence in mid-term guidance.

Product LaunchThe upcoming Rhapsido launch is seen as a positive development, with potential to gain broad payor access and drive future growth.

Strategic AcquisitionsNovartis's acquisition of Avidity's assets is expected to increase mid-term sales growth forecast from 5% to 6%, reflecting strong strategic positioning.

Bears Say

Earnings MissNovartis reported a 3% miss in EPS with a 2% operational income miss, despite in-line sales driven by key growth drivers.

Growth Rate ConcernsGuidance for FY25 remains unchanged, but implied core operational income is below consensus, suggesting a slower growth outlook.

Short-term Earnings ImpactThe inclusion of Avidity in forecasts is expected to lower EPS in the short term due to associated costs, impacting financial performance.

Novartis AG News

Novartis upgraded to Overweight from Equal Weight at Morgan Stanley

Morgan Stanley upgraded Novartis (NVS) to Overweight from Equal Weight with a price target of CHF 110, up...

5d ago

NVS

FDA moves to accelerate biosimilar development, lower drug costs

The U.S. Food and Drug Administration on Wednesday announced action to make it faster and less costly to...

6d ago

AZN

BMY

Novartis reports NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective

Novartis (NVS) presented new ianalumab data in Sjogren’s disease at a late-breaker presentation during the American College of...

7d ago

NVS

Tourmaline Bio acquisition completed by Novartis

Novartis (NVS) announced that it has successfully completed its acquisition of Tourmaline Bio (TRML). With the completion of...

8d ago

NVS

TRML

Warner Bros. Discovery upgraded, F5 downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

8d ago

NVS

Novartis announces expiration of Tourmaline Bio tender offer

Novartis (NVS) announced that its previously announced tender offer by Torino Merger Sub (TRML), a Delaware corporation and...

8d ago

NVS

TRML

Novartis price target raised to CHF 108 from CHF 105 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Novartis (NVS) to CHF 108 from CHF 105 and keeps...

8d ago

NVS

Midday Fly By: Novartis to buy Avidity, Keurig Dr Pepper beats expectations

The major averages were sharply higher near noon as the market appears to exude new optimism amid fresh...

9d ago

Video: Merger Monday with deals announced in biotechnology and banking

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

9d ago

AWK

DYN

Avidity acquisition has positive read for Dyne Therapeutics, says Morgan Stanley

After Novartis (NVS) announced an agreement to acquire Avidity Biosciences (RNA), including its proprietary Antibody Oligonucleotide Conjugate platform...

9d ago

DYN

NVS

Cautious Hold on Novartis AG Amid Mixed Ianalumab Data and Valuation Concerns

Analyst Sachin Jain of Bank of America Securities maintained a Hold rating on Novartis AG, retaining the price...

1d ago

NVS

Positive Long-Term Growth Outlook for Novartis AG Amid Temporary Setbacks

In a report released today, Thibault Boutherin from Morgan Stanley upgraded Novartis AG to a Buy, with a...

5d ago

NVS

Cautious Hold Rating on Novartis AG Amid Mixed ianalumab Study Results and Uncertain Growth Prospects

In a report released today, Sachin Jain from Bank of America Securities maintained a Hold rating on Novartis...

9d ago

NVS

Novartis AG: Balancing Promising Growth Prospects with Policy and Market Challenges

Sachin Jain, an analyst from Bank of America Securities, maintained the Hold rating on Novartis AG. The associated...

1M ago

NVS

NOT FAQ

What was Novartis AG’s price range in the past 12 months?

Novartis AG lowest stock price was €79.74 and its highest was €114.60 in the past 12 months.

What is Novartis AG’s market cap?

Novartis AG’s market cap is CHF214.11B.

When is Novartis AG’s upcoming earnings report date?

Novartis AG’s upcoming earnings report date is Feb 04, 2026 which is in 91 days.

How were Novartis AG’s earnings last quarter?

Novartis AG released its earnings results on Oct 28, 2025. The company reported €1.945 earnings per share for the quarter, missing the consensus estimate of €1.965 by -€0.02.

Is Novartis AG overvalued?

According to Wall Street analysts Novartis AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novartis AG pay dividends?

Novartis AG does not currently pay dividends.

What is Novartis AG’s EPS estimate?

Novartis AG’s EPS estimate is 1.7.

How many shares outstanding does Novartis AG have?

Novartis AG has 2,112,421,900 shares outstanding.

What happened to Novartis AG’s price movement after its last earnings report?

Novartis AG reported an EPS of €1.945 in its last earnings report, missing expectations of €1.965. Following the earnings report the stock price went down -3.625%.

Which hedge fund is a major shareholder of Novartis AG?

Currently, no hedge funds are holding shares in DE:NOT

Company Description

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG (NOT) Earnings & Revenues

Historic Earnings Reports

NOT Stock 12 Month Forecast

Average Price Target

€110.52

▲(3.10% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"75":"€75","130":"€130","88.75":"€88.8","102.5":"€102.5","116.25":"€116.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":129.32784,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€129.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110.5214166,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€110.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.918148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€95.92</span>\n  </div></div>","useHTML":true}}],"tickPositions":[75,88.75,102.5,116.25,130],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.02,112.42829538461538,113.83659076923077,115.24488615384615,116.65318153846154,118.06147692307692,119.46977230769231,120.8780676923077,122.28636307692308,123.69465846153847,125.10295384615385,126.51124923076924,127.91954461538462,{"y":129.32784,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.02,110.98164743076923,110.94329486153846,110.9049422923077,110.86658972307691,110.82823715384615,110.78988458461538,110.75153201538461,110.71317944615384,110.67482687692308,110.6364743076923,110.59812173846153,110.55976916923076,{"y":110.5214166,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.02,109.85831907692307,108.69663815384615,107.53495723076922,106.37327630769231,105.21159538461538,104.04991446153846,102.88823353846153,101.72655261538462,100.56487169230769,99.40319076923078,98.24150984615385,97.07982892307693,{"y":95.918148,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.7,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.7,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.44,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.64,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.02,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >